KPC Pharmaceuticals announced plans to sell up to 2.44 million shares in Vinet Biotech through methods such as centralized bidding and block trades, with an expected transaction value of 132 million yuan and a book cost of 113 million yuan. In the first quarter of 2026, KPC Pharmaceuticals achieved revenue of 836 million yuan, with a net loss attributable to the parent company of 142 million yuan.
KPC Pharmaceuticals IncKPC Pharmaceuticals plans to sell shares in Vinet Biotech at a loss (book cost 113M vs expected transaction value 132M, but net loss of 142M in Q1 2026 indicates financial strain).